Sunday , July 23 2017
Home / KEEP BUT DO NOT DISPLAY

KEEP BUT DO NOT DISPLAY

Brief Interruption of Sedentary Behavior Improves Glucose in Children

Researchers evaluated 28 children aged 7 to 11 years with normal weight to determine whether glucose tolerance could be improved by interrupting sitting with short, moderate-intensity walking bouts. In a random order and on different days, participants underwent one of two conditions: continuous sitting for 3 hours or sitting interrupted ...

Read More »

Coffee Puts BP Patients at Heart Attack, Diabetes Risk

According to research examining the long-term effect of coffee drinking on the risk of diabetes, coffee drinkers – especially those who drink over four cups a day – are at an increased risk of heart attacks and other cardiovascular events. Heavy coffee consumption can also trigger pre-diabetes in young adults ...

Read More »

Periodontal Disease Predicts CAC Progression in Type 1 Diabetes

In patients with type 1 diabetes, but not those without diabetes, periodontal disease duration is an independent predictor of long-term progression of coronary artery calcium (CAC), according to a study. They examined the interrelation between periodontal disease and CAC progression in individuals with and without type 1 diabetes. The prevalence ...

Read More »

OmniPod (Pod) Insulin Management System Recall

Insulet initiated a lot-specific voluntary recall of 40,846 boxes (10 Pods per box) of the OmniPod (Pod) Insulin Management System. This field corrective action is due to the possibility that some of the Pods from these lots may have a higher rate of failure than Insulet’s current manufacturing standards. For ...

Read More »

Novo Nordisk Gives Up on Victoza in T1D

Lackluster results for liraglutide as adjunct to insulin therapy: Novo Nordisk announced that it will not pursue an expanded indication for liraglutide (Victoza) as an add-on treatment to insulin for type 1 diabetes because of disappointing phase III trial results. The company released top-line results for the ADJUNCT ONE randomized ...

Read More »

Novo Moving Once-Daily Oral Version of Semaglutide Into Phase 3 Trials

They decided to initiate a phase 3a program with oral semaglutide; a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide. The decision follows the encouraging results of the proof-of-concept phase 2 trial and the subsequent consultations with regulatory authorities. Novo Nordisk intends to initiate a global phase 3a program, ...

Read More »